The New WHO Lung Cytopathology Reporting System in Practice: Diagnostic Performance and Risk of Malignancy in a Tertiary Care Setting
Diagnostic Cytopathology · 2026
DOI: 10.1002/dc.70068 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Diagnostic Cytopathology, 2026. Verfasst von Shalini Bhalla und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, King George Medical University, Lucknow, Uttar Pradesh, India. Hauptthemen laut MEDLINE: Lung Neoplasms, Cytodiagnosis, Lung. Die Arbeit nennt 26 Literaturangaben.
Abstract (Originalsprache)
Background
Respiratory cytology plays a vital role in the early diagnosis of pulmonary diseases, particularly lung cancer, which remains a leading cause of cancer‐related mortality worldwide. To enhance standardization and reduce inter‐observer variability in lung cytology reporting, the World Health Organization (WHO), in collaboration with the IAC and IARC, introduced a new five‐tiered reporting system for lung cytopathology in 2023. This study aims to retrospectively apply the WHO system to respiratory samples at a tertiary care center in India and evaluate diagnostic performance and risk of malignancy (ROM) for each category. Material and Methods A retrospective observational study was conducted from June 2022 to May 2024, analyzing 736 respiratory cytology samples, including BAL, EBUS‐TBNA, bronchial wash, bronchial brush, and sputum. Samples were reclassified using the WHO system, and 193 cases had histopathological correlation. ROM was calculated for each category, and diagnostic performance metrics sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and diagnostic accuracy (DA) were assessed using histopathology as the gold standard. Given that histologic correlation was available in only 26.2% of cases, diagnostic performance estimates were interpreted with caution and may have been influenced by verification bias.
Results
Of the total cases, 10.2% (75/736) were insufficient/inadequate, 80.1% (589/736) benign, 3.0% (22/736) atypical, 2.0% (15/736) suspicious, and 4.7% (35/736) malignant. The ROM was 43.7% for insufficient, 39.7% for benign, 50.0% for atypical, 75.0% for suspicious, and 100% for malignant. Bronchial brush demonstrated the highest DA (81.3%), while BAL had low sensitivity (10.0%) despite high specificity (98.5%). EBUS‐TBNA showed moderate sensitivity (50.0%) and lower specificity (55.6%).
Conclusion
The WHO Reporting System provides an effective framework for stratifying respiratory cytology samples. While categories such as malignant and suspicious showed high diagnostic reliability, false negatives in benign and inadequate categories highlight the need for integrated clinical and radiological assessment. Bronchial brush and wash emerged as the most diagnostically accurate specimen types. Further prospective studies are warranted to validate these findings across broader clinical settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pathology, King George Medical University, Lucknow, Uttar Pradesh, India.
- Department of Medicine, King George Medical University, Lucknow, Uttar Pradesh, India.
ORCID-Profile: Mamta Dwivedi
Zitieren
APA
Bhalla, S., Lamba, M., Dwivedi, M., Raghuvanshi, S., Maurya, M. K., & Kumar, M. (2026). The New WHO Lung Cytopathology Reporting System in Practice: Diagnostic Performance and Risk of Malignancy in a Tertiary Care Setting. Diagnostic Cytopathology. https://doi.org/10.1002/dc.70068
Vancouver
Bhalla S, Lamba M, Dwivedi M, Raghuvanshi S, Maurya MK, Kumar M. The New WHO Lung Cytopathology Reporting System in Practice: Diagnostic Performance and Risk of Malignancy in a Tertiary Care Setting. Diagnostic Cytopathology. 2026. doi:10.1002/dc.70068
BibTeX
@article{Bhalla2026,
author = {Bhalla, Shalini and Lamba, Mahak and Dwivedi, Mamta and Raghuvanshi, Shivanjali and Maurya, Malti Kumari and Kumar, Madhu},
title = {The New WHO Lung Cytopathology Reporting System in Practice: Diagnostic Performance and Risk of Malignancy in a Tertiary Care Setting},
journal = {Diagnostic Cytopathology},
year = {2026},
doi = {10.1002/dc.70068}
}
EUVIMED